CTKB vs PATH
Cytek Biosciences Inc (CTKB) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Cytek Biosciences Inc (CTKB) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported CTKB revenue for 2024-12-31 was $200.5M. Net income was -$6.0M. Revenue was up 3.9% from 2023-12-31 to 2024-12-31. CTKB currently screens at market cap $421.8M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
CTKB currently screens at market cap $421.8M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the CTKB and PATH stock pages for the full models.
Not investment advice.